Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024 - 2Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- 3WHO issues guidance on GLP-1 drugs for obesity
- 4How a Middle East War Becomes a Retail Price Hike
- 5The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- Germany sees third consecutive diesel price record after rule change
- SpaceX launches Italian Earth-observing satellite to orbit on the 1st mission of 2026 (video)
- Immortal Style: Closet Staples for Each Age
- What causes RFK Jr.’s strained and shaky voice? A neurologist explains this little-known disorder
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- Merz: 80% of Syrians in Germany expected to return within three years
- Investigating the Medical advantages of Aloe Vera
